If you have been following health news over the last few years, you have almost certainly heard the names semaglutide or liraglutide — and perhaps the brand names Ozempic, Wegovy, or Victoza. These drugs belong to a class called GLP-1 receptor agonists, and they have generated more excitement in medicine than almost anything else in recent memory. Celebrities have talked about them. Endocrinologists are prescribing them in record numbers. Waiting lists have formed. But behind the buzz is a genuine and important scientific story — one that deserves a calm, honest look.
What Is GLP-1, and Why Does It Matter?
GLP-1 stands for glucagon-like peptide-1. It is a hormone your body produces naturally, mainly in the small intestine, after you eat. Its job is elegantly simple: it signals to your pancreas to release insulin, tells your liver to slow down glucose production, and — crucially — sends a message to your brain that you are full. In other words, GLP-1 is part of the body's own system for managing blood sugar and appetite.
In people with type 2 diabetes or obesity, this system can become sluggish or dysregulated. GLP-1 receptor agonists are synthetic molecules designed to mimic this hormone, but they last far longer in the body than the natural version — sometimes an entire week with a single injection. This sustained effect is what makes them therapeutically powerful.
Who Are These Medicines Actually For?
GLP-1 receptor agonists were originally developed to treat type 2 diabetes, and that remains one of their primary approved uses. Over time, clinical trials revealed something striking: patients were also losing significant amounts of weight. This led regulators in many countries — including India's CDSCO — to approve some of these drugs specifically for chronic weight management in adults with obesity or with weight-related health conditions such as high blood pressure or high cholesterol.
It is important to understand that these are prescription medicines, not over-the-counter supplements. A qualified doctor will assess whether a GLP-1 medication is appropriate for you based on your full medical history, other medications, and individual health goals. They are not a first resort, and they are not for everyone.
The Benefits: What the Evidence Actually Shows
Blood Sugar Control
For people with type 2 diabetes, GLP-1 receptor agonists are highly effective at lowering HbA1c — a marker of average blood sugar over three months. Multiple large clinical trials have confirmed this. Unlike some older diabetes medicines, they carry a low risk of causing dangerously low blood sugar (hypoglycaemia) on their own, which is a meaningful safety advantage.
Weight Loss
The STEP trials for semaglutide and the SCALE trials for liraglutide showed average weight reductions of 10–15% of body weight over roughly a year, with higher doses achieving even more in some participants. For context, this is significantly better than most previous weight-loss medications. For individuals who have struggled with obesity for years despite diet and exercise, this can be life-changing.
Heart and Kidney Protection
Perhaps the most surprising and exciting finding has been the cardiovascular benefit. The SELECT trial, published in 2023 in the New England Journal of Medicine, found that semaglutide reduced the risk of major cardiovascular events — heart attack, stroke, and cardiovascular death — by 20% in adults with obesity and established heart disease who did not have diabetes. Separate studies have also suggested kidney-protective effects. These findings have shifted how cardiologists and nephrologists think about these drugs.
Other Emerging Benefits
- Reduction in liver fat in people with non-alcoholic fatty liver disease (NAFLD)
- Improvements in sleep apnoea symptoms (early trial data is encouraging)
- Possible reduction in inflammation markers, though more research is needed
- Some early evidence suggesting benefit in polycystic ovarian syndrome (PCOS) — an area of active research
The Side Effects: What You Should Know Before Starting
No medicine this powerful comes without trade-offs. The side effects of GLP-1 receptor agonists are real, and being informed about them is part of making a good decision with your doctor.
Common Side Effects (Usually Manageable)
The most frequently reported side effects are gastrointestinal in nature. They are more common when starting the medicine or when the dose is increased, and they often improve over a few weeks as the body adjusts.
- Nausea — the most commonly reported complaint
- Vomiting, particularly after eating large or fatty meals
- Diarrhoea or constipation
- Stomach discomfort, bloating, or indigestion
- Reduced appetite (this is actually the intended effect, but can feel unpleasant initially)
- Burping or acid reflux
Doctors typically manage these by starting at a low dose and increasing it gradually over several weeks. Eating smaller meals, avoiding very greasy or spicy food, and staying well-hydrated can all help.
Less Common but More Serious Side Effects
- Pancreatitis (inflammation of the pancreas): Rare but serious. Seek immediate medical attention if you experience severe, persistent abdominal pain radiating to the back.
- Gallstones: Rapid weight loss of any kind can increase gallstone risk; GLP-1 medications are no exception.
- Injection site reactions: Redness, itching, or small lumps at the injection site are occasionally reported.
- Increased heart rate: A modest increase in resting heart rate has been noted in some users; your doctor will monitor this.
- Muscle loss: Some weight lost with these medications may come from lean muscle mass rather than fat alone — a reason why protein intake and resistance exercise are strongly encouraged alongside treatment.
Who Should Not Take GLP-1 Medicines
These medications are not suitable for everyone. Your doctor will specifically avoid prescribing them if you have a personal or family history of a rare type of thyroid cancer called medullary thyroid carcinoma, or a condition called MEN2 (Multiple Endocrine Neoplasia type 2). They are also generally not recommended during pregnancy or breastfeeding. Always give your doctor your complete medical history.
An Important Question: What Happens When You Stop?
This is one of the most honest conversations to have with your healthcare provider. Current evidence suggests that much of the weight lost returns when people stop taking GLP-1 medications, particularly if lifestyle changes have not been solidified. This does not mean the medicines have failed — it reflects the chronic nature of obesity as a condition. For many people, long-term or indefinite treatment may be part of the plan, similar to how someone with hypertension might take blood pressure medication for years. The decision is personal, medical, and financial, and deserves careful discussion.
These are not miracle drugs, but they are genuinely significant medicines. Used appropriately, with proper medical oversight and lifestyle support, they can make a meaningful difference in people's lives.
A Practical Takeaway
GLP-1 receptor agonists represent a genuine step forward in the management of type 2 diabetes and obesity — conditions that affect hundreds of millions of people, including a very large proportion of Indians. The evidence for their benefits in blood sugar control, weight reduction, and cardiovascular protection is robust and peer-reviewed. The side effects, while real, are generally manageable with proper medical guidance.
If you are curious about whether a GLP-1 medication could be right for you, the best first step is a conversation with your endocrinologist, diabetologist, or general physician. Bring your questions. Ask about costs, duration of treatment, what to expect in the first weeks, and how to support the medicine with nutrition and movement. These are tools — powerful ones — but they work best as part of a broader, honest commitment to your health.
This article is for informational purposes only and does not constitute medical advice. Please consult a qualified healthcare professional before starting, stopping, or changing any medication.